ID 93

Drug Profile

ID 93

Alternative Names: ID 93/AP10-602; ID-93/GLA-SE; ID93 + AP10-602; ID93 + GLA-SE; Tuberculosis vaccine adjuvanted - Aeras/Infectious Disease Research Institute; Tuberculosis vaccine recombinant Mycobacterium tuberculosis protein ID93/adjuvant GLA-SE - Aeras/IDRI

Latest Information Update: 21 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Infectious Disease Research Institute
  • Developer Aeras; Infectious Disease Research Institute
  • Class Recombinant fusion proteins; Synthetic vaccines; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Tuberculosis

Most Recent Events

  • 19 Feb 2018 Phase-I development is ongoing for Tuberculosis (Prevention) in USA (IM, Injection)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Tuberculosis(Prevention) in USA (IM, Injection)
  • 17 Sep 2015 The Infectious Disease Research Institute plans a phase II trial for Tuberculosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top